Jinling Pharmaceutical Co Ltd (000919) - Net Assets

Latest as of September 2025: CN¥4.85 Billion CNY ≈ $709.28 Million USD

Based on the latest financial reports, Jinling Pharmaceutical Co Ltd (000919) has net assets worth CN¥4.85 Billion CNY (≈ $709.28 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.02 Billion ≈ $881.50 Million USD) and total liabilities (CN¥1.18 Billion ≈ $172.22 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Jinling Pharmaceutical Co Ltd to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥4.85 Billion
% of Total Assets	80.46%
Annual Growth Rate	12.71%
5-Year Change	41.23%
10-Year Change	65.79%
Growth Volatility	41.33

Jinling Pharmaceutical Co Ltd - Net Assets Trend (1996–2024)

This chart illustrates how Jinling Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Jinling Pharmaceutical Co Ltd asset portfolio for the complete picture of this company's asset base.

Annual Net Assets for Jinling Pharmaceutical Co Ltd (1996–2024)

The table below shows the annual net assets of Jinling Pharmaceutical Co Ltd from 1996 to 2024. For live valuation and market cap data, see Jinling Pharmaceutical Co Ltd (000919) total market value.

Year	Net Assets	Change
2024-12-31	CN¥4.85 Billion ≈ $709.50 Million	+31.58%
2023-12-31	CN¥3.68 Billion ≈ $539.22 Million	+1.60%
2022-12-31	CN¥3.63 Billion ≈ $530.75 Million	+2.62%
2021-12-31	CN¥3.53 Billion ≈ $517.22 Million	+2.95%
2020-12-31	CN¥3.43 Billion ≈ $502.38 Million	+0.25%
2019-12-31	CN¥3.42 Billion ≈ $501.14 Million	+5.50%
2018-12-31	CN¥3.25 Billion ≈ $475.00 Million	+6.29%
2017-12-31	CN¥3.05 Billion ≈ $446.88 Million	+0.03%
2016-12-31	CN¥3.05 Billion ≈ $446.75 Million	+4.39%
2015-12-31	CN¥2.92 Billion ≈ $427.95 Million	+6.31%
2014-12-31	CN¥2.75 Billion ≈ $402.55 Million	+6.86%
2013-12-31	CN¥2.57 Billion ≈ $376.72 Million	+4.41%
2012-12-31	CN¥2.47 Billion ≈ $360.82 Million	+6.04%
2011-12-31	CN¥2.33 Billion ≈ $340.26 Million	+5.73%
2010-12-31	CN¥2.20 Billion ≈ $321.83 Million	+7.03%
2009-12-31	CN¥2.05 Billion ≈ $300.70 Million	+9.39%
2008-12-31	CN¥1.88 Billion ≈ $274.89 Million	-3.64%
2007-12-31	CN¥1.95 Billion ≈ $285.26 Million	+14.76%
2006-12-31	CN¥1.70 Billion ≈ $248.57 Million	+8.72%
2005-12-31	CN¥1.56 Billion ≈ $228.64 Million	+6.35%
2004-12-31	CN¥1.47 Billion ≈ $214.99 Million	+6.53%
2003-12-31	CN¥1.38 Billion ≈ $201.81 Million	+11.14%
2002-12-31	CN¥1.24 Billion ≈ $181.58 Million	+11.82%
2001-12-31	CN¥1.11 Billion ≈ $162.39 Million	+4.62%
2000-12-31	CN¥1.06 Billion ≈ $155.22 Million	+4.20%
1999-12-31	CN¥1.02 Billion ≈ $148.96 Million	+225.38%
1998-12-31	CN¥312.85 Million ≈ $45.78 Million	+38.47%
1997-12-31	CN¥225.93 Million ≈ $33.06 Million	+32.78%
1996-12-31	CN¥170.16 Million ≈ $24.90 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Jinling Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 165816237300.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥1.66 Billion	43.74%
Common Stock	CN¥623.71 Million	16.45%
Other Comprehensive Income	CN¥3.09 Million	0.08%
Other Components	CN¥1.51 Billion	39.73%
Total Equity	CN¥3.79 Billion	100.00%

Jinling Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Jinling Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Transcat Inc NASDAQ:TRNS	$672.66 Million
Zhang Xiaoquan Inc. SHE:301055	$672.73 Million
Samsung Electro Mechanics Pref KO:009155	$672.97 Million
Kardemir Karabuk Demir Celik Sanayi ve Ticaret AS Class D IS:KRDMD	$673.14 Million
Sichuan Goldstone Orient New Material Equipment Co Ltd SHE:300434	$672.53 Million
MTY Food Group Inc TO:MTY	$672.49 Million
Advanced Nano Products Co. Ltd KQ:121600	$672.32 Million
Arvinas Inc NASDAQ:ARVN	$672.23 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jinling Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 3,042,611,967 to 3,791,090,837, a change of 748,478,870 (24.6%).
Net income of 40,409,795 contributed positively to equity growth.
Dividend payments of 63,242,928 reduced retained earnings.
Share repurchases of 20,282,577 reduced equity.
Other comprehensive income decreased equity by 334,542.
Other factors increased equity by 791,929,122.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥40.41 Million	+1.07%
Dividends Paid	CN¥63.24 Million	-1.67%
Share Repurchases	CN¥20.28 Million	-0.54%
Other Comprehensive Income	CN¥-334.54K	-0.01%
Other Changes	CN¥791.93 Million	+20.89%
Total Change	CN¥-	24.60%

Book Value vs Market Value Analysis

This analysis compares Jinling Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.16x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 21.89x to 1.16x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1996-12-31	CN¥0.34	CN¥7.39	x
1997-12-31	CN¥0.44	CN¥7.39	x
1998-12-31	CN¥0.62	CN¥7.39	x
1999-12-31	CN¥2.02	CN¥7.39	x
2000-12-31	CN¥2.10	CN¥7.39	x
2001-12-31	CN¥2.13	CN¥7.39	x
2002-12-31	CN¥2.27	CN¥7.39	x
2003-12-31	CN¥2.53	CN¥7.39	x
2004-12-31	CN¥2.67	CN¥7.39	x
2005-12-31	CN¥2.85	CN¥7.39	x
2006-12-31	CN¥3.10	CN¥7.39	x
2007-12-31	CN¥3.50	CN¥7.39	x
2008-12-31	CN¥3.38	CN¥7.39	x
2009-12-31	CN¥3.67	CN¥7.39	x
2010-12-31	CN¥3.90	CN¥7.39	x
2011-12-31	CN¥4.08	CN¥7.39	x
2012-12-31	CN¥4.21	CN¥7.39	x
2013-12-31	CN¥4.37	CN¥7.39	x
2014-12-31	CN¥4.60	CN¥7.39	x
2015-12-31	CN¥4.85	CN¥7.39	x
2016-12-31	CN¥5.04	CN¥7.39	x
2017-12-31	CN¥5.13	CN¥7.39	x
2018-12-31	CN¥5.43	CN¥7.39	x
2019-12-31	CN¥5.71	CN¥7.39	x
2020-12-31	CN¥5.67	CN¥7.39	x
2021-12-31	CN¥5.81	CN¥7.39	x
2022-12-31	CN¥5.94	CN¥7.39	x
2023-12-31	CN¥6.04	CN¥7.39	x
2024-12-31	CN¥6.40	CN¥7.39	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jinling Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 1.07%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 1.23%
• Asset Turnover: 0.54x
• Equity Multiplier: 1.61x
Recent ROE (1.07%) is below the historical average (10.42%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1996	18.44%	15.94%	0.80x	1.45x	CN¥14.36 Million
1997	41.33%	30.69%	0.98x	1.37x	CN¥70.11 Million
1998	31.64%	28.96%	0.78x	1.39x	CN¥67.15 Million
1999	11.09%	31.81%	0.30x	1.15x	CN¥11.06 Million
2000	11.23%	32.57%	0.30x	1.15x	CN¥13.02 Million
2001	10.11%	21.76%	0.35x	1.32x	CN¥1.23 Million
2002	11.26%	20.44%	0.41x	1.35x	CN¥14.42 Million
2003	10.36%	15.54%	0.52x	1.28x	CN¥4.58 Million
2004	8.35%	11.22%	0.56x	1.33x	CN¥-22.15 Million
2005	11.00%	12.77%	0.67x	1.28x	CN¥14.35 Million
2006	13.00%	14.67%	0.68x	1.31x	CN¥46.62 Million
2007	17.42%	19.85%	0.65x	1.34x	CN¥131.01 Million
2008	4.85%	4.62%	0.81x	1.29x	CN¥-87.76 Million
2009	11.95%	11.23%	0.80x	1.33x	CN¥36.02 Million
2010	9.81%	8.92%	0.79x	1.40x	CN¥-3.78 Million
2011	8.04%	7.32%	0.76x	1.44x	CN¥-40.24 Million
2012	6.76%	6.23%	0.72x	1.51x	CN¥-68.68 Million
2013	7.08%	5.98%	0.79x	1.50x	CN¥-64.33 Million
2014	8.50%	7.11%	0.77x	1.56x	CN¥-34.88 Million
2015	8.51%	6.46%	0.84x	1.58x	CN¥-36.30 Million
2016	7.09%	5.03%	0.93x	1.52x	CN¥-73.77 Million
2017	5.30%	4.30%	0.83x	1.49x	CN¥-121.55 Million
2018	8.83%	8.34%	0.75x	1.42x	CN¥-31.90 Million
2019	5.05%	5.73%	0.61x	1.44x	CN¥-142.48 Million
2020	3.28%	3.74%	0.58x	1.50x	CN¥-192.09 Million
2021	4.12%	4.29%	0.63x	1.52x	CN¥-172.15 Million
2022	3.52%	3.94%	0.59x	1.52x	CN¥-194.14 Million
2023	3.28%	3.58%	0.61x	1.50x	CN¥-204.61 Million
2024	1.07%	1.23%	0.54x	1.61x	CN¥-338.70 Million

Industry Comparison

This section compares Jinling Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $1,347,197,696
Average return on equity (ROE) among peers: 4.46%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Jinling Pharmaceutical Co Ltd (000919)	CN¥4.85 Billion	18.44%	0.24x	$672.54 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$2.84 Billion	-41.97%	9.13x	$1.22 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$638.89 Million	0.88%	0.70x	$438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$1.05 Billion	10.46%	0.19x	$5.18 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.07 Billion	3.83%	0.46x	$2.81 Billion
Wedge Industrial Co Ltd (000534)	$1.29 Billion	11.69%	1.47x	$2.95 Billion
Yunnan Baiyao Group Co Ltd (000538)	$35.11 Million	18.13%	0.80x	$13.85 Billion
Hainan Haiyao Co Ltd (000566)	$5.08 Billion	1.71%	1.08x	$949.23 Million
Tus Pharmaceutical Group Co Ltd (000590)	$141.91 Million	11.01%	0.32x	$391.07 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$994.58 Million	2.01%	2.11x	$1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$332.48 Million	26.89%	0.68x	$3.30 Billion

About Jinling Pharmaceutical Co Ltd

SHE:000919 China Drug Manufacturers - Specialty & Generic

Market Cap

$672.54 Million

CN¥4.60 Billion CNY

Market Cap Rank

#11048 Global

#3281 in China

Share Price

CN¥7.39

Change (1 day)

+0.96%

52-Week Range

CN¥6.55 - CN¥8.91

All Time High

CN¥16.21